Cost-effectiveness of liraglutide versus lixisenatide as add-on therapies to basal insulin in type 2 diabetes.

by Åsa Ericsson, Divina Glah, Maria Lorenzi, Jeroen P Jansen, Adam Fridhammar
Published 2018-01-01

Resource use and outcomes associated with initiation of injectable therapies for patients with type 2 diabetes mellitus

by Richard Brice, Sharon Shelley, Pankaj Chaturvedi, Divina Glah, Donna Ashley, Monica Hadi
Published 2015-01-01